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Summary
 
Intranasal Herpes simplex virus type 1 (HSV-1) infection of mice caused pneumonia. Manifes-
tations of the disease included: histological pneumonitis, pulmonary influx of lymphocytes, de-
creased pulmonary compliance, and decreased survival. Immunohistochemical staining demon-
strated iNOS induction and the nitrotyrosine antigen in the lungs of infected, but not
uninfected mice, suggesting that nitric oxide contributes to the development of pneumonia.
To elucidate the role of nitric oxide in the pathogenesis of HSV-1 pneumonia, infected mice
 
were treated either with the inhibitor of nitric oxide synthase activity, N
 
G
 
-monomethyl-
 
l
 
-argi-
nine (
 
l
 
-NMMA), or, as a control, with PBS or 
 
d
 
-NMMA. 
 
l
 
-NMMA treatment decreased the
histological evidence of pneumonia and reduced the bronchoalveolar lavage lymphocyte num-
ber to one-quarter of the total measured in control-treated mice. 
 
l
 
-NMMA treatment signifi-
cantly improved survival and pulmonary compliance of HSV-1–infected mice. Strikingly, the
 
l
 
-NMMA–mediated suppression of pneumonia occurred despite the presence of a 17-fold
higher pulmonary viral titer. Taken together, these data demonstrated a previously unrecognized
role of nitric oxide in HSV-1–induced pneumonia. Of note, suppression of pneumonia oc-
curred despite higher pulmonary virus content; therefore, our data suggest that HSV-1 pneu-
monia is due to aspects of the inflammatory response rather than to direct viral cytopathic effects.
 
H
 
erpes simplex virus type 1 (HSV-1)
 
1
 
 pneumonia is of
considerable clinical significance, particularly in new-
borns and immunocompromised patients (1–6), but the
pathogenesis is poorly understood. A broader mechanistic
understanding of the disease would provide a basis for pro-
phylactic and therapeutic strategies in HSV-1 pneumonia
patients (7).
Nitric oxide (NO) produced by the inducible isoform of
NO-synthase (iNOS, NOS2) plays a multifunctional role in
the cytotoxicity of activated macrophages, in the patho-
physiology of septic shock, and in the suppression of car-
diac function (8, 9). Studies of iNOS-deficient mutant
mice demonstrated that NO contributes to endotoxic shock
and to the immune response to bacteria and parasites (10, 11).
Experiments with N
 
G
 
-monomethyl-
 
l
 
-arginine (
 
l
 
-NMMA)
or aminoguanidine, inhibitors of nitric oxide synthase (NOS),
showed the involvement of NO in influenza virus pneu-
monia (12), graft versus host disease (13), experimental au-
toimmune encephalomyelitis (14), and alloreactivity (15).
NO production can be beneficial as an antiviral effector
mechanism against HSV-1 and other viruses (16–19). On
the other hand, NO may also be detrimental by contribut-
ing to pathology during viral infections (20–22); for exam-
ple, NO induced by gp41 of HIV-1 contributes to the de-
mentia seen in AIDS patients (23).
NO is crucial for the pathogenesis of influenza virus
pneumonia in mice (12). Inhibition of iNOS by 
 
l
 
-NMMA
treatment improved survival of virus-infected mice without
exerting an effect on the pulmonary viral titer. Thus, NO is
important for the development of influenza virus pneumo-
 
1
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nia but not as an antiviral effector mechanism (12). In con-
trast, HSV-1 is susceptible to NO (18, 19). Furthermore,
NO is produced during HSV-1 infection (24). Therefore,
we wanted to determine whether iNOS inhibition in
HSV-1–induced pneumonia would lead to a higher pul-
monary viral burden and exacerbation of pneumonitis, or
alternatively, to a reduction in proinflammatory effects of
NO with suppression of pneumonitis. Therefore, inhibi-
tion of NO production could affect the development of vi-
ral pneumonitis in opposite ways: it could worsen the disease
by diminishing the antiviral effect of NO, or it could improve
the pneumonitis by reducing a proinflammatory mechanism.
Our data suggest that NO is an important mediator of
HSV-1 pneumonia. Inhibition of NO production by
 
l
 
-NMMA treatment led to a significantly improved sur-
vival rate and to a strong suppression of HSV-1–induced
pneumonitis despite the presence of a higher pulmonary
virus content. These results suggest that iNOS inhibition is
beneficial; the proinflammatory effects of NO are more
important for the pathology of HSV-1 pneumonia than the
antiviral effects of NO.
 
Materials and Methods
 
Mice.
 
Female CBA/J (H-2
 
k
 
) mice, purchased from The Jack-
son Laboratory (Bar Harbor, ME), were used at 12–26 wk of age.
 
Infection of Mice.
 
Mice were infected intranasally with 1 
 
3
 
10
 
6
 
 PFU HSV-1, strain KOS 1.1 (25), kindly provided by Drs.
R. Finberg and J. Brubaker (Dana-Farber Cancer Institute, Bos-
ton, MA), given in a final volume of 0.03 ml sterile 0.9% sodium
chloride (Fujisawa USA, Inc., Deerfield, IL) per mouse. For sur-
vival experiments, mice were infected with 2 LD
 
50
 
 (5 
 
3
 
 10
 
7
 
 PFU
per mouse in this system). The virus stock used for this study was
clarified supernatant derived from infected Vero cell cultures (Ad-
vanced Biotechnologies, Inc., Columbia, MD). The Vero cells
and culture media were screened and shown to be free of myco-
plasma and endotoxin contamination.
 
Treatment of Mice with NMMA.
 
l
 
-NMMA (Alexis Corp., San
Diego, CA) dissolved in PBS (pH 7.4), was given at a dose of 2
mg/day i.p. in a volume of 0.2 ml from the day of virus infection
until analysis of mice as described (12). Infected control mice
were treated with the same amount of N
 
G
 
-monomethyl-
 
d
 
-argin-
ine (
 
d
 
-NMMA) (Sigma Chem. Co., St. Louis, MO) or with PBS.
Treatment of uninfected mice with 
 
l
 
-NMMA did not affect any
of the tested parameters, when compared to uninfected, untreated
mice (data not shown).
 
Tissue Sampling.
 
Mice were euthanized by CO
 
2
 
 asphyxiation
7 d after infection, blood was collected by cardiac puncture, and
the trachea was cannulated using a 19-gauge tubing adapter (Bec-
ton Dickinson, Rutherford, NJ) inserted through an incision im-
mediately distal to the larynx. Bronchoalveolar lavage (BAL) was
performed with sterile 0.9% sodium chloride, using three separate
1.0-ml aliquots, each of which was infused and withdrawn five
times. The cells were centrifuged and resuspended in RPMI me-
dium containing 10% FCS for further analysis. When indicated,
the left lung was processed for virus titration, and the right lower
lobe of the lung was used for histological examination. Previous
studies demonstrated that the virus titration and histology were
not affected by the lung lavage procedure (Adler, H., L. Kobzik,
and I.J. Rimm, unpublished results).
 
Flow Cytometry.
 
BAL lymphocytes were stained for flow cy-
tometry and analyzed using CellQuest on a FACScan
 
Ò
 
 (Becton
Dickinson). The following monoclonal antibodies, conjugated ei-
ther with fluorescein isothiocyanate or phycoerythrin were used
for staining: anti-B220, anti-CD4, anti-CD8, anti-CD3, anti-
 
a
 
/
 
b
 
T cell receptor, and anti-
 
g
 
/
 
d
 
 T cell receptor (PharMingen, San
Diego, CA). Fluorescein isothiocyanate- or phycoerythrin-conju-
gated isotype-matched antibodies were used as negative controls.
 
Virus Titration and Histology.
 
The left lung was homogenized
by grinding in 1 ml of sterile 0.9% sodium chloride and stored
frozen at 
 
2
 
80
 
8
 
C. Viral titers were determined from thawed ali-
quots by plaque assay on Vero cells, and the number of plaques
was determined after staining the cells with crystal violet.
For histology, the lower lobe of the right lung was inflated
with O.C.T. compound (Miles Inc., Elkhart, IN) and fixed in
10% formalin in PBS (Fisher Scientific, Fair Lawn, NJ). After fix-
ation, the samples were dehydrated and embedded in paraffin.
5-
 
m
 
m-thick sections were cut and stained with hematoxylin/
eosin (H/E). The samples were analyzed and scored microscopi-
cally in a blind study on coded slides as described (26). Two types
of pathological changes were scored separately. Histopathologic
changes around airways and vessels were termed periluminal, and
histopathologic changes within the alveolar parenchyma were
scored as parenchymal abnormalities. A final score of pneumonitis
from 0 to 9 was assigned for each pathologic process (periluminal
and parenchymal) as the product of severity grade by the extent.
The score that is presented reflects the sum of both scores.
 
Staining for iNOS and Nitrotyrosine.
 
For immunohistochemis-
try, mouse lungs were inflated by intratracheal instillation of
O.C.T. compound and immediately frozen in a dry ice/2-methyl-
butane bath. Immunostaining was performed on 8-
 
m
 
M cryostat
sections using a standard peroxidase anti-peroxidase protocol (27).
Primary antibodies included rabbit anti-NOS2 or anti-nitrotyrosine
(Upstate Biotechnology Inc., Lake Placid, NY) or normal rabbit
IgG (Sigma) used at 1 
 
m
 
g/ml. Diaminobenzidine was used as a
chromogen, and slides were counterstained with hematoxylin be-
fore microscopic evaluation.
 
Pulmonary Function Test.
 
As parameter of lung function, dy-
namic compliance (C
 
dyn
 
, defined as the increase in lung volume
obtained from a given increase in distending pressure at points of
zero flow) was determined in vivo 7 d after infection. C
 
dyn
 
 is a
parameter that generally reflects the condition of the lung paren-
chyma, and is decreased by pulmonary interstitial edema, or in-
flammation, or by any condition that reduces alveolar patency.
We used a previously described plethysmographic technique for
making measurements of lung function (28). Anesthetized mice
(70–90 mg/kg Na pentobarbital i.p.) underwent placement of a
tracheostomy tube for mechanical ventilation (7 ml/kg/breath,
150 breaths/min) and thoracotomy to eliminate any effect that
the chest wall may have on pulmonary function.
 
Determination of HSV-1–specific Antibodies.
 
HSV-1–specific IgG2a
antibodies in serum samples of mice 7 d after infection were de-
termined using a specific ELISA (29). In brief, microtiter plates
coated with HSV-1 Macintyre Strain Viral Lysate (Advanced Bio-
technologies Inc., Columbia, MD) were incubated with serial dilu-
tions of a standard serum or test samples, and after extensive washing,
alkaline phosphatase conjugated goat anti–mouse IgG2a (South-
ern Biotechnology, Birmingham, AL) was added. The plates
were developed using 
 
p
 
-nitrophenyl phosphate (Sigma) in DEA
buffer. The reaction was stopped with 3 N NaOH, and absor-
bance was read at 405 nm using an ELISA reader. In all assays,
samples and standards were run at least in duplicates. The calcula-
tion of the HSV-1–specific antibodies was performed by the 
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method of Zollinger and Boslego (30). As expected, no HSV-1–spe-
cific IgG2a antibodies were detected in sera of uninfected mice.
In contrast, in all sera of infected mice, regardless of their treat-
ment, HSV-1–specific IgG2a antibodies were readily detected (data
not shown). Thus, all infected animals seroconverted in response
to infection.
 
Statistical Analyses.
 
The Student’s 
 
t
 
 test (unpaired) and the
Wilcoxon rank sum test were used for data analysis where appro-
priate. Treatment-group differences in the viral titer per lung
were analyzed by one-way analysis of variance (ANOVA).
 
Results
 
Intranasal Infection of Mice with HSV-1 Led to the Develop-
ment of Pneumonia.
 
Intranasal infection of mice with HSV-1
led to the development of pneumonia. Histopathological
changes in infected animals were most evident at day 7 after
infection. The pneumonia was characterized histologically
by mononuclear infiltrates (Fig. 1, compare 
 
A
 
 with 
 
D
 
), an
increase in the histology score (Fig. 2, compare uninfected/
 
l
 
-NMMA with infected/PBS), an increase in the number
of cells recovered by BAL (Fig. 3, 
 
A
 
 and 
 
B
 
, compare unin-
fected/
 
l
 
-NMMA with infected/PBS), a change in the CD4/
 
CD8 ratio (Table 1, compare uninfected/untreated with
infected/PBS), and by a decrease in lung compliance (see
below).
 
Immunolocalization of iNOS and Nitrotyrosine Antigens.
 
To demonstrate the induction of iNOS and the production
of NO during HSV-1–induced pneumonia, we performed
immunohistochemistry on lung tissue of uninfected and
infected mice at days 3 and 7 after infection, using antibod-
ies against murine iNOS and nitrotyrosine. iNOS was de-
tected within inflammatory cells in infected mice, but not
in uninfected mice. Similarly, nitrotyrosine staining was
observed in infected mice, but not in uninfected mice (data
not shown). Thus, these results demonstrated that NO is
indeed produced during the course of HSV-1 infection,
confirming previous data (24). NO reacts with O
 
2
 
2
 
 to gen-
erate peroxynitrite, which is involved in microbial killing as
well as toxicity (9, 31, 32). Nitrotyrosine is a marker of
peroxynitrite generation, since nitrotyrosine is a product
resulting from peroxynitrite action (12).
 
L
 
-NMMA Treatment Decreased Histological Evidence of Pneu-
monia.
 
Since iNOS and nitrotyrosine staining demonstrated
the involvement of NO in HSV-1 pneumonia, experi-
Figure 1. l-NMMA treatment decreased histological evidence of pneumonia. Mice were infected with HSV-1 and treated with l-NMMA, d-NMMA,
or PBS. Photomicrographs of lung sections stained with H/E show the histopathological changes at day 7 after infection. (A) infected, treated with PBS;
(B) infected, treated with l-NMMA; (C) infected, treated with d-NMMA; (D) uninfected, treated with l-NMMA. Original magnification: (A and C)
3100; (B and D) 340. 
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ments were designed to test the effect of 
 
l
 
-NMMA treat-
ment on HSV-1 pneumonia. Mice were infected intrana-
sally with 1 
 
3
 
 10
 
6
 
 PFU of HSV-1 per mouse, and
histological examination of lungs was performed at day 7
after infection. In HSV-1–infected, PBS-treated control
mice, pneumonitis was characterized by mononuclear infil-
trates around vessels and bronchioles (periluminal), and a
diffuse intraalveolar infiltrate consisting mainly of mononu-
clear cells (parenchymal) (Fig. 1 
 
A
 
). In contrast, the devel-
opment of pneumonia was strongly suppressed in mice
treated with 
 
l
 
-NMMA (Fig. 1 
 
B
 
). The suppression of
pneumonia was specific, since the biologically inactive
stereoisomer 
 
d
 
-NMMA did not show this effect (Fig. 1
 
C
 
). Normal lungs were observed in uninfected mice either
treated with 
 
l
 
-NMMA (Fig. 1 
 
D
 
) or left untreated (data
not shown). Histological scores reflecting the periluminal
and parenchymal changes in the lungs of infected mice were
significantly lower in infected animals treated with 
 
l
 
-NMMA,
compared to infected mice treated with d-NMMA or PBS.
In fact, treatment with l-NMMA suppressed the pneu-
monitis  scores nearly to the level observed in uninfected mice
(Fig. 2).
L-NMMA Treatment Reduced the Number of Cells Recovered
by BAL. Intranasal infection with HSV-1 led to a pro-
nounced increase in the total cell number as well as in the
lymphocyte number recovered by BAL at day 7 after infec-
tion, when compared to uninfected animals (Fig. 3, A and
B). l-NMMA treatment, however, markedly inhibited the
influx of inflammatory cells. In contrast, treatment with
d-NMMA showed no effect. Thus, the BAL data were
consistent with the results obtained by histology.
Since lymphocytes were the predominant cells recruited
to the lung after HSV-1 infection, we analyzed whether
treatment with l-NMMA changed the composition of the
lymphocyte population. Neither treatment with l-NMMA
nor d-NMMA altered the lymphocyte subpopulations in
infected mice, when compared with infected, PBS-treated
control mice (Table 1). All groups of infected mice showed
a dominance of CD3+ T cells. The CD4/CD8 ratio changed
from 2:1 in uninfected mice to z1:4 in infected mice. The
vast majority of the cells were a/b TCR1; very low num-
bers of g/d TCR1 cells were detected (data not shown).
L-NMMA Treatment Improved Lung Compliance in Infected
Mice. To assess the effect of l-NMMA treatment on the
development of pneumonia, we also measured lung com-
pliance as a parameter of in vivo global lung function. Pul-
monary compliance is a quantitative measure of broncho-
pulmonary injury; additionally these results estimate the
Figure 2. l-NMMA treatment decreased pneumonitis scores. HSV-
1–infected mice were treated with l-NMMA, d-NMMA or PBS daily
from the day of virus infection. Pathology scores were determined 7 d af-
ter infection. Data represent means 6 SE of 6–13 mice in each group,
pooled from 3–5 separate experiments. The asterisk indicates a significant
difference from both infected/d-NMMA and infected/PBS (P ,0.01;
Student’s t test).
Figure 3. Treatment with l-NMMA suppressed the influx of cells re-
covered by BAL. Mice were treated with l-NMMA, d-NMMA or PBS.
BAL cell numbers were determined 7 d after infection. (A) Total cell
number recovered by BAL. (B) Lymphocyte numbers were calculated us-
ing total cell number in BAL and percent lymphocytes gated during
FACSÒ-analysis. Values presented are means 6 SE of 6–13 mice per
group, pooled from 3–5 separate experiments. The asterisks indicate a sig-
nificant difference from both infected/d-NMMA and infected/PBS (P
,0.003; Student’s t test).1537 Adler et al.
magnitude of the physiological derangement resulting from
the infection. A reduction in lung compliance, or the most
closely related human pulmonary function test parameter,
total lung capacity, to 30% of a previously normal level
would be considered a life-threatening change of pulmo-
nary status. Lung compliance was 0.032 6 0.002 (mean 6
SE; n 5 3) in uninfected mice treated with l-NMMA,
which was similar to values measured in uninfected, un-
treated mice (data not shown). In infected, d-NMMA–
treated mice, compliance was reduced to 0.010 6 0.003
(n 5 3), i.e., to 30% of the level in uninfected mice. In
contrast, treatment of infected mice with l-NMMA signif-
icantly improved lung compliance to 0.029 6 0.001 (n 5
4), when compared to infected, but d-NMMA–treated
mice (P ,0.004; Student’s t test). Thus, l-NMMA treat-
ment improved lung compliance of infected animals nearly
to the levels measured in uninfected mice.
L-NMMA Treatment Increased Survival after HSV-1 Infec-
tion. Mice were infected intranasally with 5 3 107 PFU
of HSV-1 per mouse (z2 LD50), and treated with l-NMMA
or PBS daily for 7 d after infection. Survival of mice was
monitored over a period of 14 d after infection. l-NMMA
treatment led to a significant improvement in the survival
rate (Fig. 4).
L-NMMA Treatment Increased Viral Titers in the Lung.
To assess the role of NO in the antiviral defense, pulmo-
nary viral titers were determined at days 2, 3, 4, and 7 after
infection. Similar viral titers were observed at day 2 after
infection between mice treated either with l-NMMA or
PBS (Fig. 5). However, a 17-fold higher pulmonary viral
titer was observed at day 3 in the l-NMMA–treated mice,
when compared to mice treated with PBS. At day 4 after
Table 1. Treatment with L-NMMA Did Not Affect the Lymphocyte Subset Distribution at Day 7 after Intranasal HSV-1 Infection
Lymphocyte subsets (%)
Uninfected/untreated
or L-NMMA
(n 5 13)
Infected/
L-NMMA
(n 5 13)
Infected/
D-NMMA
(n 5 7)
Infected-
PBS
(n 5 6)
Ratio CD4/CD8 2:1 1:4 1:4 1:5
B2201 1.8 6 0.4 2.4 6 0.6 3.4 6 0.4 2.5 6 0.6
CD31 40.2 6 8.5 73.2 6 6.2 82.4 6 1.4 82.7 6 1.6
CD41 20.4 6 5.7 15.0 6 0.9 14.9 6 1.7 13.1 6 1.6
CD81 11.0 6 1.8 56.6 6 7.5 65.7 6 3.2 68.7 6 4.0
Animals were treated from day 0 to 6 with L-NMMA, D-NMMA, or PBS. BAL was performed at day 7 after infection, and the recovered cells were
analyzed by FACSÒ analysis. Values presented are means 6 SEM of the number of mice shown in brackets. Data are pooled from 3–5 separate ex-
periments.
Figure 4. l-NMMA treatment increased survival of mice after intrana-
sal infection with HSV-1. 10 mice per group were infected with 2 LD50
of HSV-1, and treated with l-NMMA or PBS daily from the day of virus
infection until day 7. l-NMMA treatment significantly improved the sur-
vival rate (P 5 0.0001; Wilcoxon rank sum test).
Figure 5. Treatment with l-NMMA led to a significant higher pulmonary
viral titer. Animals were treated from day 0 until analysis with l-NMMA
(triangles) or PBS (circles). Each data point represents the pulmonary viral
titer (Log PFU/Lung) obtained from an individual animal. The means for
the groups are shown by the solid lines. The viral titer in the l-NMMA–
treated group at day 3 post infection was significantly higher than in PBS-
treated animals. The difference in viral titer per lung between the l-NMMA
and PBS group was significant (P 5 0.0199 using ANOVA).1538 Suppression of HSV-1 Pneumonia in Mice by Inhibition of iNOS
infection, a 2.5-fold higher viral titer was measured in the
l-NMMA–treated mice. Virus was cleared at day 7 after
infection in all groups of mice. The difference in pulmo-
nary viral titer between the l-NMMA and PBS group was
significant.
The significantly higher pulmonary viral titer observed at
day 3 after infection in the l-NMMA–treated mice was not
accompanied by an increase in the extent of pneumonitis,
as demonstrated by a comparable histopathology score and
a similar number of BAL inflammatory cells for both the
l-NMMA– and PBS-treated mice (Table 2).
Discussion
Intranasal infection with HSV-1 led to the development
of pneumonia. We demonstrated that inhibition of NO
production led to a significantly improved survival rate as
well as to a strong suppression of the pneumonia despite
the presence of a 17-fold higher viral titer in the lung at 3 d
after infection. These results suggested that the proinflam-
matory effects of NO are more important than its antiviral
effector functions for the development of HSV-1–induced
pneumonia. Furthermore, these results also support the no-
tion that the inflammatory response to HSV-1 infection,
rather than direct viral cytopathic effects, is critical for the
development of pneumonia. Immunopathology is involved
in other HSV-1 infections, for example, an immune-medi-
ated pathogenesis that involves T cells is the basis for herpetic
stromal keratitis (33, 34). A T cell–mediated immunopa-
thology is also believed to be involved in the pathogenesis
of CMV-induced pneumonia (35). Consequently, reduc-
tion of virus growth did not prevent, but did moderate,
murine CMV pneumonitis (36, 37). Therefore, treatment
of HSV-1–induced pneumonia with antiviral drugs alone
might not be sufficient, and a modulation of components
of the immune response may also be required. Administra-
tion of selective inhibitors of NOS activity in the treatment
of inflammatory airway diseases has been suggested (38, 39).
In our study, inhibition of NO production led to a 17-fold
increase in pulmonary viral titer at 3 d after infection, con-
firming earlier reports on an antiviral activity of NO against
HSV (18, 19). Therefore, it was remarkable that inhibi-
tion of NO production strongly suppressed the development
of pneumonia. A recent study of the pathogenesis of influ-
enza virus-induced pneumonia in mice demonstrated that
inhibition of NO production by l-NMMA administration
resulted in a significant improvement of the survival rate of
virus-infected mice (12). However, in this case, l-NMMA
treatment did not significantly affect the propagation of in-
fluenza virus in vivo.
Inhibition of NO production might lead to suppression
of pneumonia by preventing the influx of inflammatory
cells to the lung. NO can cause vasodilation, leading to al-
terations in blood flow, which may promote leukocyte in-
filtration. NO can also modulate leukocyte adhesion to en-
dothelial cells and alter microvascular permeability during
inflammation (9, 31). In vivo neutralization of IFN-g re-
duced the magnitude of the pulmonary cellular infiltrate
after pulmonary influenza virus infection (40). Thus, IFN-g
may recruit leukocytes into inflamed lung parenchyma. IFN-g
is a strong iNOS inducer, able to induce NO production as
a single stimulus (41). Thus, the mechanism of IFN-g ac-
tion in this system may be to increase NO production.
IFN-g is also induced during HSV-1 infection of the lung
(Adler, H., and I.J. Rimm, unpublished results).
NO or its reaction products might directly cause tissue
damage and the release of cytokines and chemokines, which
then attract inflammatory cells to the site of virus infection.
Influenza A virus infection selectively induced chemokines
responsible for the predominant mononuclear leukocyte in-
filtration in virally infected tissue (42). NO induces NF-kB
binding activity and may lead to secretion of proinflamma-
tory lymphokines and cytokines from activated lympho-
cytes (8, 43).
Treatment with l-NMMA clearly did not prevent the
development of pneumonia by interfering with the viral
infection of the lung for the following reasons: (a) higher
viral titers were detected in l-NMMA treated animals (Fig.
5). (b) The change in the CD4/CD8 ratio of the BAL lym-
phocytes, which is characteristic for a viral infection of the
lung (44), was not affected by the treatment (Table 1). (c)
All infected animals seroconverted in response to the intra-
nasal infection (data not shown).
Although there is currently controversy regarding the
production of NO by human macrophages (45), increasing
numbers of reports demonstrate iNOS induction or NO
production in human diseases (46–50). Moreover, NO can
be produced by iNOS of a number of other cells types in-
cluding for example pulmonary epithelial cells (31, 39, 51).
In conclusion, we demonstrated an important role of NO
in HSV-1–induced pneumonia in mice that may have sub-
stantial implications for the therapy of this disease.
Table 2. The Higher Pulmonary Viral Titer at Day 3 after 
Intranasal HSV-1 Infection Was Not Associated with Increased 
Pulmonary Pathology
Infected/
L-NMMA
Infected/
PBS
Histology score 0.3 6 0.2 0.8 6 0.4
Total cell number in
BAL (3104) 69.0 6 7.0 72.0 6 17.0
Lymphocyte number
in BAL (3104) 8.3 6 1.4 6.5 6 3.6
Pulmonary virus content
(Log PFU/lung) 3.7 6 0.2* 2.7 6 0.4
Animals were treated from day 0 until analysis with L-NMMA or PBS.
Histopathology scores, BAL cell numbers and pulmonary viral titers
were determined in parallel 3 d after infection. Values presented are
means 6 SE of five individual mice per group.
*The difference in viral titer per lung between the L-NMMA and PBS
group was significant (P ,0.05; Student’s t test).1539 Adler et al.
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